A citation-based method for searching scientific literature

M Xing. Endocr Relat Cancer 2005
Times Cited: 955







List of co-cited articles
685 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
40


Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R Michael Tuttle,[...]. JAMA 2013
609
22

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian,[...]. J Clin Oncol 2015
346
19

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
592
16


Molecular genetics and diagnosis of thyroid cancer.
Yuri E Nikiforov, Marina N Nikiforova. Nat Rev Endocrinol 2011
624
14

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
437
14

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
731
14

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S Cooper, Gerard M Doherty, Bryan R Haugen, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger,[...]. Thyroid 2009
13

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
13

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
411
12

TERT promoter mutations in thyroid cancer.
Rengyun Liu, Mingzhao Xing. Endocr Relat Cancer 2016
212
12

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
12

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
898
12

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
Marina N Nikiforova, Edna T Kimura, Manoj Gandhi, Paul W Biddinger, Jeffrey A Knauf, Fulvio Basolo, Zhaowen Zhu, Riccardo Giannini, Giuliana Salvatore, Alfredo Fusco,[...]. J Clin Endocrinol Metab 2003
769
12

Progress in molecular-based management of differentiated thyroid cancer.
Mingzhao Xing, Bryan R Haugen, Martin Schlumberger. Lancet 2013
365
12

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
405
11


BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
Paula Soares, Vítor Trovisco, Ana Sofia Rocha, Jorge Lima, Patrícia Castro, Ana Preto, Valdemar Máximo, Tiago Botelho, Raquel Seruca, Manuel Sobrinho-Simões. Oncogene 2003
505
10


BRAF mutation in papillary thyroid carcinoma.
Yoram Cohen, Mingzhao Xing, Elizabeth Mambo, Zhongmin Guo, Guogun Wu, Barry Trink, Uziel Beller, William H Westra, Paul W Ladenson, David Sidransky. J Natl Cancer Inst 2003
641
9

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Hyeyeun Lim, Susan S Devesa, Julie A Sosa, David Check, Cari M Kitahara. JAMA 2017
8

Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
442
8

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Julio C Ricarte-Filho, Mabel Ryder, Dhananjay A Chitale, Michael Rivera, Adriana Heguy, Marc Ladanyi, Manickam Janakiraman, David Solit, Jeffrey A Knauf, R Michael Tuttle,[...]. Cancer Res 2009
375
8

The prevalence and prognostic value of BRAF mutation in thyroid cancer.
Electron Kebebew, Julie Weng, Juergen Bauer, Gustavo Ranvier, Orlo H Clark, Quan-Yang Duh, Daniel Shibru, Boris Bastian, Ann Griffin. Ann Surg 2007
344
8

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
Marina N Nikiforova, Roy A Lynch, Paul W Biddinger, Erik K Alexander, Gerald W Dorn, Giovanni Tallini, Todd G Kroll, Yuri E Nikiforov. J Clin Endocrinol Metab 2003
489
7

Thyroid cancer.
Maria E Cabanillas, David G McFadden, Cosimo Durante. Lancet 2016
681
7

Targeted Therapy in Thyroid Cancer: State of the Art.
L Valerio, L Pieruzzi, C Giani, L Agate, V Bottici, L Lorusso, V Cappagli, L Puleo, A Matrone, D Viola,[...]. Clin Oncol (R Coll Radiol) 2017
74
9

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
889
7

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
Tae Hyuk Kim, Young Joo Park, Jung Ah Lim, Hwa Young Ahn, Eun Kyung Lee, You Jin Lee, Kyung Won Kim, Seo Kyung Hahn, Yeo Kyu Youn, Kwang Hyun Kim,[...]. Cancer 2012
307
7

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Xiaoli Liu, Shen Qu, Rengyun Liu, Chunjun Sheng, Xiaoguang Shi, Guangwu Zhu, Avaniyapuram Kannan Murugan, Haixia Guan, Hongyu Yu, Yangang Wang,[...]. J Clin Endocrinol Metab 2014
206
7

BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
C Durante, E Puxeddu, E Ferretti, R Morisi, S Moretti, R Bruno, F Barbi, N Avenia, A Scipioni, A Verrienti,[...]. J Clin Endocrinol Metab 2007
279
7


TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
346
7


Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Lara A Dunn, Eric J Sherman, Shrujal S Baxi, Vatche Tchekmedyian, Ravinder K Grewal, Steven M Larson, Keith S Pentlow, Sofia Haque, R Michael Tuttle, Mona M Sabra,[...]. J Clin Endocrinol Metab 2019
102
7

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho, Ravinder K Grewal, Rebecca Leboeuf, Eric J Sherman, David G Pfister, Desiree Deandreis, Keith S Pentlow, Pat B Zanzonico, Sofia Haque, Somali Gavane,[...]. N Engl J Med 2013
489
7

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
193
7

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Keith T Flaherty, Jeffery R Infante, Adil Daud, Rene Gonzalez, Richard F Kefford, Jeffrey Sosman, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Nageatte Ibrahim,[...]. N Engl J Med 2012
6

RAS mutations in thyroid cancer.
Gina M Howell, Steven P Hodak, Linwah Yip. Oncologist 2013
113
6

Novel treatments for anaplastic thyroid carcinoma.
Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Ilaria Ruffilli, Concettina La Motta, Sabrina Rosaria Paparo, Armando Patrizio, Roberto Vita, Salvatore Benvenga, Gabriele Materazzi,[...]. Gland Surg 2020
43
13

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Zhi Liu, Peng Hou, Meiju Ji, Haixia Guan, Kimberly Studeman, Kirk Jensen, Vasily Vasko, Adel K El-Naggar, Mingzhao Xing. J Clin Endocrinol Metab 2008
291
6

Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin.
N Motoi, A Sakamoto, T Yamochi, H Horiuchi, T Motoi, R Machinami. Pathol Res Pract 2000
70
8

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
6


BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.
A Zoghlami, F Roussel, J-C Sabourin, J-M Kuhn, J-P Marie, D Dehesdin, O Choussy. Eur Ann Otorhinolaryngol Head Neck Dis 2014
24
25

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
695
6

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.
Hiroyuki Namba, Masahiro Nakashima, Tomayoshi Hayashi, Naomi Hayashida, Shigeto Maeda, Tatiana I Rogounovitch, Akira Ohtsuru, Vladimir A Saenko, Takashi Kanematsu, Shunichi Yamashita. J Clin Endocrinol Metab 2003
435
6

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
S Filetti, C Durante, D Hartl, S Leboulleux, L D Locati, K Newbold, M G Papotti, A Berruti. Ann Oncol 2019
288
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.